EGFR and head and neck squamous cell carcinoma: Therefore, since numerous studies have clearly demonstrated that monoclonal anti-EGFR antibodies have significant clinical activity when administered in combination with irinotecan as a first- or second-line agent [4], this therapeutic drug has been assessed in the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) in combination with radiotherapy.